Loading...
•
Dec 31, 2022
Aclaris Therapeutics Q4 2022 Earnings Report
Aclaris Therapeutics reported financial results for the fourth quarter and full year of 2022.
Key Takeaways
Aclaris Therapeutics reported a net loss of $27.6 million for the fourth quarter of 2022, compared to a net loss of $22.8 million for the fourth quarter of 2021. Total revenue was $7.8 million for the fourth quarter of 2022, compared to $1.5 million for the fourth quarter of 2021.
Aclaris anticipates cash, cash equivalents and marketable securities as of December 31, 2022 will be sufficient to fund operations through the end of 2025.
Net loss was $27.6 million for the fourth quarter of 2022 compared to $22.8 million for the fourth quarter of 2021.
Total revenue was $7.8 million for the fourth quarter of 2022 compared to $1.5 million for the fourth quarter of 2021.
Research and development expenses were $21.1 million for the quarter ended December 31, 2022 compared to $14.1 million for the prior year period.
Aclaris Therapeutics
Aclaris Therapeutics
Aclaris Therapeutics Revenue by Segment
Revenue by Segment
Contract research Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
Aclaris Therapeutics anticipates that its cash, cash equivalents and marketable securities as of December 31, 2022 will be sufficient to fund its operations through the end of 2025, without giving effect to any potential business development transactions or financing activities.
Revenue & Expenses
Visualization of income flow from segment revenue to net income